Stockscreener 앱 받기
4.78
8.64%
0.38
시간 외 거래:
4.83
0.05
+1.05%
전일 마감가:
$4.40
열려 있는:
$4.51
하루 거래량:
13.41M
Relative Volume:
2.25
시가총액:
$809.90M
수익:
$76.20M
순이익/손실:
$-17.37M
주가수익비율:
525.27
EPS:
0.0091
순현금흐름:
$-75.81M
1주 성능:
-1.85%
1개월 성능:
-12.61%
6개월 성능:
+141.41%
1년 성능:
+613.75%
1일 변동 폭
$4.41
$5.15
1주일 범위
$4.36
$8.21
52주 변동 폭
$0.40
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.78 | 745.52M | 76.20M | -17.37M | -75.81M | 0.0091 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Sean Mccarthy Sells 118,969 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) CFO Sells $124,053.66 in Stock - MarketBeat
Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) SVP Sells 31,492 Shares of Stock - MarketBeat
CytomX (CTMX) CMO sells 21,279 shares to cover RSU tax obligations - Stock Titan
CytomX Therapeutics SVP Belvin sells $202k in stock - Investing.com
CytomX Therapeutics (CTMX) CEO sells shares to cover RSU tax obligations - Stock Titan
Tax-driven share sale by CytomX (CTMX) chief scientist on RSU vesting - Stock Titan
CytomX (NASDAQ: CTMX) CFO sells 19,323 shares for tax withholding - Stock Titan
CytomX Therapeutics Raises $234 Million in Equity Offering - TipRanks
CytomX prices $5.30 public offering to raise ~$234.4M; includes pre-funded warrants - TradingView
CytomX (NASDAQ: CTMX) prices $234.4M stock and pre-funded warrant deal - Stock Titan
CytomX Therapeutics (NASDAQ:CTMX) Given New $16.00 Price Target at Barclays - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade - MarketBeat
CTMX Sees Price Target Raised to $16 by Jefferies Today | CTMX S - GuruFocus
Jefferies Maintains Buy on CTMX (CytomX Therapeutics) March 18, 2026 - Meyka
Latham Watkins Advises CytomX Therapeutics on Offering of Common Stock Pre Funded Warrants - Latham & Watkins LLP
CytomX (NASDAQ: CTMX) offers 45.99M shares and 1.18M pre‑funded warrants - Stock Titan
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
Why Is CytomX Therapeutics Stock Falling On Wednesday? - Benzinga
CytomX Stocks Slide Amidst Profit Woes and Revenue Shortfall - timothysykes.com
CytomX Therapeutics (CTMX) Gets Price Target Boost from Guggenhe - GuruFocus
CTMX: Key Managers in Recent Offering - GuruFocus
Barclays raises its price target on CytomX Therapeutics, Inc. (CTMX) to $10 and maintains an overweight rating - MSN
CytomX Therapeutics (NASDAQ:CTMX) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price (CTMX) - Seeking Alpha
CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $15.00 at Guggenheim - MarketBeat
CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN
HC Wainwright Has Bearish Estimate for CTMX Q1 Earnings - MarketBeat
CytomX Therapeutics Prices $250 Million Securities Offering; Shares Up Pre-Bell - marketscreener.com
CytomX prices $250M stock offering at $5.30 per share By Investing.com - Investing.com South Africa
CytomX Therapeutics Confronts Rising AI Regulatory Risks and Cost Pressures - The Globe and Mail
Biotech CytomX prices $250M stock sale to fund Varseta-M - Stock Titan
CytomX Therapeutics (CTMX) Launches $250 Million Public Offering - GuruFocus
CTMX Analyst Rating Update: Wedbush Raises Price Target by 83% | - GuruFocus
CytomX Therapeutics prices public offering of 45,990,567 shares at $5.30 per share - marketscreener.com
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - Bitget
CytomX Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock - Quiver Quantitative
Cytomx’s expanded readout supports late-stage testing of masked EpCAM ADC - BioCentury
CytomX Therapeutics: Still Some Ways To Go (NASDAQ:CTMX) - Seeking Alpha
CytomX’s $250M Stock Offering: Boost for Varseta-M Development - StocksToTrade
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
CytomX Therapeutics (NASDAQ:CTMX) Trading Down 4.2% on Disappointing Earnings - MarketBeat
CytomX Therapeutics price target raised to $11 from $6 at Wedbush - TipRanks
CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at Wedbush - MarketBeat
A Look At CytomX Therapeutics (CTMX) Valuation After Varseta M Phase 1 Expansion Data And Earnings Update - simplywall.st
Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform - BioSpace
HighVista Strategies LLC Invests $820,000 in CytomX Therapeutics, Inc. $CTMX - MarketBeat
CTMX: JP Morgan Upgrades CytomX Therapeutics to Overweight, Rais - GuruFocus
CytomX Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CTMX) 2026-03-17 - Seeking Alpha
Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Launches $250 Million Stock Offering to Fund Cancer Drug Development - Intellectia AI
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):